MEXICO: Ion Gel ZCM-25®: A New Paradigm for Public Health Savings — Reducing Amputations and Hospital Burden

Ion Gel ZCM-25® accelerates healing, reduces amputations, and generates significant savings in the management of chronic wounds in diabetes.

Ion Gel ZCM-25® is more than a topical antimicrobial. It's a tool that reduces complications, optimizes resources, and transforms chronic wound care into public health.

— Kevin Rude, CEO de Ion Biotechnology México

PUERTO VALLARTA, JALISCO, MEXICO, July 10, 2025 / EINPresswire.com / -- Ion Gel ZCM-25 ® demonstrates significant potential to generate economic efficiencies in public healthcare systems by reducing chronic wound complications, amputations, and prolonged hospitalizations.

Ion Biotechnology Mexico is proud to announce the launch of a data-driven initiative

highlighting the clinical and economic impact of Ion Gel ZCM-25 ® in large-scale healthcare settings. As chronic wounds, particularly diabetic ulcers, become an increasing burden on public systems, the ability to prevent amputations and accelerate healing emerges as a critical cost-saving strategy.

Chronic Wounds and the Economic Cost
According to the World Health Organization, diabetic foot ulcers affect up to 25% of people with diabetes during their lifetime. In Mexico alone, amputations due to diabetes represent more than 70,000 procedures annually, resulting in billions of pesos in direct care costs and long-term disability.

Traditional management relies on systemic antibiotics, repeated debridement, and prolonged hospital stays—approaches that not only strain budgets but also fail to address the problem of antimicrobial resistance.

Ion Gel ZCM-25® Ion
Gel ZCM-25® is formulated with IBAL (Ion Biotechnology Aqueous Ligands) technology, which enables the coordinated release of bioactive ions—zinc, copper, magnesium, sulfur, and hydrogen—capable of:
Rapidly disrupting bacterial membranes and biofilms, eliminating pathogens in minutes.

Modulating markers of oxidative stress, reducing inflammation by more than 50% in 24 hours.

Promotes epithelialization and tissue granulation, shortening healing cycles by weeks.

This multi-action profile can reduce cumulative treatment costs by reducing infectious recurrences, systemic antibiotic consumption, and hospitalization days.

Economic Modeling and Projected Results
Based on clinical case data and cost models applied in public hospitals, the following impacts were estimated per 1,000 patients with diabetic ulcers:

30% reduction in amputations.

22 fewer days of hospital stay per patient.

45% reduction in antibiotic costs.

Annual savings of more than 1 billion pesos in public health networks such as the IMSS.

Illustrative Clinical Case
In one documented case, a 56-year-old patient with type 2 diabetes and peripheral vascular disease faced a high risk of amputation. During 104 days of treatment with Ion Gel ZCM-25 ® combined with silver dressings, the wound achieved complete closure without recurrence of infection, preventing amputation and generating an estimated savings of 350,000 pesos in direct care costs.

A Strategic Ally for Health Systems

About Ion Biotechnology Mexico
Ion Biotechnology develops science-based, GMP-certified solutions for advanced infection control and wound healing. Ion Gel ZCM-25 ® is COFEPRIS approved as a Class II Medical Device and is available for institutional purchase and clinical use.